Genome Insight, Inc. Announces Groundbreaking Research Collaboration with Shriners Children’s for Patients with Adolescent Idiopathic Scoliosis

Project aims to unravel the genetic etiology of Adolescent Idiopathic Scoliosis (AIS) by leveraging Genome Insight’s whole-genome sequencing analysis and interpretation platform to bridge the knowledge gap, revolutionizing AIS diagnosis, treatment, and prevention.

SAN DIEGO--()--Genome Insight, Inc. and Shriners Children’s have launched a new human, whole-genome sequencing research project called Unraveling the Genetic Mysteries of Adolescent Idiopathic Scoliosis: A Groundbreaking Research Collaboration.

Combining Shriners Children’s clinical expertise with Genome Insight’s advanced genomics capabilities, this collaboration aims to identify key genetic factors, influencing AIS development. The project will analyze genomic data from 100 adolescent patients treated at Shriners Children’s. Utilizing Genome Insight’s state-of-the-art whole-genome sequencing analysis and interpretation platform, the team will examine the complete DNA sequences of these patients. This approach will uncover genetic variants and alterations associated with AIS, providing valuable insights into the complex genetic landscape of AIS. The goal is to develop targeted interventions, personalized treatment approaches, and potential preventive measures.

“This research collaboration holds immense promise in advancing our understanding of adolescent idiopathic scoliosis,” said Erin Connolly-Strong, Chief Medical Science Officer, Genome Insight, Inc. “While there have been previous studies that have utilized whole-genome sequencing, this will be the largest whole-genome sequencing of the AIS cohort to date, resulting in more robust data.”

“In a more affordable whole-genome sequencing era, a high performance clinical bioinformatics tool is vital more than ever. Shriners Children’s pediatric research in rare disorders will certainly gain value in combining our efforts with Genome Insight to extract substantial genetic information from large patient cohorts and hopefully harness the treatment of these debilitating disorders” said Dr. Kamran Shazand, Director of the Shriners Children’s Genomics Institute and principal investigator on this collaboration.


Genome Insight, Inc. is a global team, with headquarters in San Diego, California. The company was brought to fruition by physicians with a common vision to deliver unparalleled bioinformatics that merges whole-genome and patient data with to deliver first-in-class research and discovery, precision diagnostics and treatments. The company’s mission is to improve how patients are diagnosed and treated, by unlocking the full potential of personalized genomic data.


Shriners Children’s is changing lives every day through innovative pediatric specialty care, world-class research and outstanding medical education. Our multiple locations in the United States, Canada and Mexico provide care for children with orthopedic conditions, burn injuries, spinal cord injuries and other spine disorders, rehabilitation, sports injuries and craniofacial conditions. All care is provided regardless of the families’ ability to pay or insurance status. Shriners Children’s has treated more than 1.5 million children from more than 170 countries since its founding in 1922.

For more information on the care provided by Shriners Children’s, go to

Shriners Hospitals for Children is a 501(c)(3) nonprofit organization and relies on the generosity of donors. All donations are tax deductible to the fullest extent permitted by law.


Sohee Cho


Sohee Cho